Automating Sample Preparation Workflows for Hybrid LC-MS/MS Bioanalysis of Protein Therapeutics: Quantification of Etanercept Using Affinity Purification and Digestion

Significance of the Topic

Quantitative bioanalysis of therapeutic proteins such as etanercept is critical for pharmacokinetic studies, dose optimization and regulatory compliance. An automated workflow can reduce hands-on time, improve reproducibility and support high-throughput demands in drug discovery and quality control.

Aims and Study Overview

This work aimed to develop and validate a fully automated sample preparation protocol combining immunoaffinity capture and enzymatic digestion for hybrid LC-MS/MS quantification of the fusion protein etanercept. Automated and manual workflows were compared stepwise to ensure equivalence, with a target lower limit of quantification (LLOQ) of 1 ng/mL in rat plasma.

Methodology and Instrumentation Used

Critical steps included magnetic bead affinity purification followed by tryptic digestion. Key instrumentation and consumables were:

• Liquid handler: Hamilton STAR with STARWorks for Waters ProteinWorks automation software
• Affinity reagents: Magne Protein A beads for generic IgG capture; High Capacity Magne Streptavidin beads coupled with goat anti-human biotinylated IgG for etanercept specificity
• Digestion kit: ProteinWorks Auto-eXpress Low 5 Digest Kit (denaturation, reduction, alkylation, digestion, quench)
• UPLC: ACQUITY UPLC I-Class Plus system with Peptide BEH C18 column (2.1 × 150 mm, 1.7 µm, 300 Å)
• Mass spectrometry: Xevo TQ-XS tandem quadrupole, ESI+, MRM detection controlled by MassLynx and quantified via TargetLynx

Main Results and Discussion

Automated protein A capture of infliximab achieved peak areas within ±15% of manual prep and %RSDs < 20%. The goat anti-human protocol for etanercept showed equivalent performance with %RSDs < 10%. A full quantitative assay demonstrated linearity from 1 to 10,000 ng/mL (r2 > 0.997), QC accuracy between 96–107% and precision ≤ 10% RSD. Example MRM transitions for etanercept surrogate peptides ICTCRPGWYCALSK and CSSDQVETQACTR yielded clear, interference-free chromatograms at the LLOQ.

Benefits and Practical Applications

The automated workflow offers:

• Walk-away operation freeing up scientist time
• Enhanced reproducibility and reduced human error
• Sensitivity suitable for preclinical PK and biomarker studies
• Scalability for high-throughput screening in bioanalytical labs

Future Trends and Applications

Automation of complex multi-step sample prep will evolve with integration of digital process monitoring and AI-driven optimization. Expanding applications may include advanced glycopeptide analysis, multiplexed biologic panels and coupling with microfluidic platforms for single-cell proteomics. Continued refinement will drive faster, more reliable assays for next-generation biotherapeutics.

Conclusion

A stepwise approach to automating immunoaffinity capture and digestion on a Hamilton STAR platform produced a robust hybrid LC-MS/MS assay for etanercept quantification in plasma. The method met stringent bioanalytical validation criteria with an LLOQ of 1 ng/mL, demonstrating that complex sample preparation can be reliably automated to enhance throughput and consistency.

References

1. Delobel A. Advances in LC/MS methodologies for complex glycoprotein characterization: case study etanercept. Quality Assistance 2017.
2. Grand View Research. Biologics market size worth $399.5 billion by 2025 at 3.9% CAGR. 2017.
3. Igea Hub Pharmaceutical Club. Analysis of the best selling drugs in 2017: etanercept revenue $7.98 billion. 2018.
4. Skyline targeted mass spec environment. MacCoss Labs, University of Washington. 2017.
5. Promega. Magne Protein A and Protein G beads antibody purification protocol.
6. Promega. High Capacity Magne Streptavidin beads and goat anti-human biotinylated IgG binding mechanism.